ArticleHepatology international2020
Effect of COVID-19 on patients with compensated chronic liver diseases.
Article in Hepatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- The impact of HBV infection on clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.Epidemiology and infection · 2023Pooled it
- Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis.World journal of gastroenterology · 2023Pooled it
- Correlation between COVID-19 and hepatitis B: A systematic review.World journal of gastroenterology · 2022Pooled it
- The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID-19: A systematic review and meta-analysis of cohort studies.The clinical respiratory journal · 2022Pooled it
- Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies.BMJ open gastroenterology · 2021Pooled it
- Co-Infection With Hepatitis E Virus and SARS-CoV-2 in a Lymphoma Patient.Journal of medical virology · 2025Article
- Observational
- Evaluating the protective effectiveness and risk factors of ursodeoxycholic acid on COVID-19 among outpatients.Frontiers in pharmacology · 2024Article
- Comorbidities of COVID-19 Patients.Medicina (Kaunas, Lithuania) · 2023Review
- Effect of COVID-19 Pandemic on Patients Who Have Undergone Liver Transplantation: Retrospective Cohort Study.Journal of clinical medicine · 2023Article
- Liver injury at admission and outcomes in patients with COVID-19 disease: a prospective cohort study.Annals of medicine and surgery (2012) · 2023Article
- Impact of COVID-19 on Patients with Decompensated Liver Cirrhosis.Diagnostics (Basel, Switzerland) · 2023Article
- Acute-on-chronic liver failure in patients with severe acute respiratory syndrome coronavirus 2 infection.World journal of hepatology · 2023Review
- Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease.Frontiers in cellular and infection microbiology · 2023Article
- Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis.JHEP reports : innovation in hepatology · 2022Article
- Impact of age, gender and comorbidities affecting the severity of COVID-19 infection in Kashmir.Journal of family medicine and primary care · 2022Article
- COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later.Journal of viral hepatitis · 2022Review
- COVID-19 and liver diseases.Egyptian liver journal · 2022Review
- Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients.Journal of clinical and translational hepatology · 2021Review
- Coronavirus disease 2019 gastrointestinal and liver manifestations in adults: A review.JGH open : an open access journal of gastroenterology and hepatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimCytokine storm has been reported in patients with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. We examine the incidence of acute on chronic liver failure (ACLF) in COVID-19 patients with pre-existing compensated chronic liver disease (CLD).
methodsFrom 20 Jan 2020 to 7 Feb 2020, we studied 140 consecutive COVID-19 patients admitted to either Fuyang Second People's Hospital (FYSPH), Anhui or the Fifth Medical Center of Chinese PLA General Hospital (PLAGH) in Beijing, China. Pre-existing CLD includes those with liver cirrhosis assessed by APRI/FIB-4 score and /or ultrasound; NAFLD as identified by either ultrasound or hepatic steatosis index with significant liver fibrosis and chronic hepatitis B (CHB) or hepatitis C (CHC) infection. The diagnosis, grading of severity and clinical management of COVID-19 patients complied to the guideline and clinical protocol issued by the China National Health Commission. All patients had liver function test at least twice weekly till discharge with full recovery or death.
resultsIn total, 3 had liver cirrhosis, 6 patients had CHB, 13 had NAFLD with significant liver fibrosis (one also had CHB). On admission, none had liver decompensation. COVID-19 disease progression was significantly less frequent in non-CLD patients (10/118 8.5%) than CLD patients (13/22 59.1%, p < 0.001). One patient with CLD had acute-on-chronic liver failure (ACLF).
conclusionDisease progression is significantly higher in those COVID-19 patients with CLD as compared to those with no CLD. ACLF can also occur in patient with pre-existing compensated CLD who had severe COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.